Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir
Abstract COVID‐19 in cancer patients on immunosuppressive agents for the treatment of immune‐related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID‐19, and furthe...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4459 |
_version_ | 1827979107900588032 |
---|---|
author | Naohiro Oda Keiji Miyoshi Daisuke Morichika Yuka Beika Takahiro Taki Reo Mitani Toshiaki Okada Ichiro Takata |
author_facet | Naohiro Oda Keiji Miyoshi Daisuke Morichika Yuka Beika Takahiro Taki Reo Mitani Toshiaki Okada Ichiro Takata |
author_sort | Naohiro Oda |
collection | DOAJ |
description | Abstract COVID‐19 in cancer patients on immunosuppressive agents for the treatment of immune‐related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID‐19, and further clinical trials are warranted. |
first_indexed | 2024-04-09T21:31:58Z |
format | Article |
id | doaj.art-e1cf2529d28f48dfb3f0dab67d7fb366 |
institution | Directory Open Access Journal |
issn | 2050-0904 |
language | English |
last_indexed | 2024-04-09T21:31:58Z |
publishDate | 2021-07-01 |
publisher | Wiley |
record_format | Article |
series | Clinical Case Reports |
spelling | doaj.art-e1cf2529d28f48dfb3f0dab67d7fb3662023-03-27T08:34:50ZengWileyClinical Case Reports2050-09042021-07-0197n/an/a10.1002/ccr3.4459Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivirNaohiro Oda0Keiji Miyoshi1Daisuke Morichika2Yuka Beika3Takahiro Taki4Reo Mitani5Toshiaki Okada6Ichiro Takata7Department of Internal Medicine Fukuyama City Hospital Fukuyama JapanDepartment of Respiratory Medicine Fukuyama Medical Center Fukuyama JapanDepartment of Respiratory Medicine Fukuyama Medical Center Fukuyama JapanDepartment of Respiratory Medicine Fukuyama Medical Center Fukuyama JapanDepartment of Internal Medicine Fukuyama City Hospital Fukuyama JapanDepartment of Internal Medicine Fukuyama City Hospital Fukuyama JapanDepartment of Respiratory Medicine Fukuyama Medical Center Fukuyama JapanDepartment of Internal Medicine Fukuyama City Hospital Fukuyama JapanAbstract COVID‐19 in cancer patients on immunosuppressive agents for the treatment of immune‐related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID‐19, and further clinical trials are warranted.https://doi.org/10.1002/ccr3.4459baricitinibCOVID‐19immune checkpoint inhibitorimmune‐related adverse eventlung cancer |
spellingShingle | Naohiro Oda Keiji Miyoshi Daisuke Morichika Yuka Beika Takahiro Taki Reo Mitani Toshiaki Okada Ichiro Takata Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir Clinical Case Reports baricitinib COVID‐19 immune checkpoint inhibitor immune‐related adverse event lung cancer |
title | Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir |
title_full | Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir |
title_fullStr | Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir |
title_full_unstemmed | Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir |
title_short | Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir |
title_sort | successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab induced arthritis by methylprednisolone baricitinib and remdesivir |
topic | baricitinib COVID‐19 immune checkpoint inhibitor immune‐related adverse event lung cancer |
url | https://doi.org/10.1002/ccr3.4459 |
work_keys_str_mv | AT naohirooda successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT keijimiyoshi successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT daisukemorichika successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT yukabeika successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT takahirotaki successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT reomitani successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT toshiakiokada successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir AT ichirotakata successfultreatmentofcriticalcoronavirusdisease2019inapatientwithlungcancerconcomitantwithpembrolizumabinducedarthritisbymethylprednisolonebaricitinibandremdesivir |